Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma

• Published in: The oncologist (Dayton, Ohio) Vol. 23; no. 2; pp. 157 - e21
• Main Authors: Ghiaseddin, Ashley, Reardon, David, Massey, Woody, Mannerino, Alex, Lipp, Eric S., Herndon, James E., McSherry, Frances, Desjardins, Annick, Randazzo, Dina, Friedman, Henry S., Peters, Katherine B.
• Format: Journal Article
• Language: English
• Published: United States AlphaMed Press 01.02.2018
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bevacizumab - administration & dosage; Brain Neoplasms - drug therapy; Brain Neoplasms - pathology; Clinical Trial Results; Female; Follow-Up Studies; Glioma - drug therapy; Glioma - pathology; Humans; Male; Middle Aged; Neoplasm Recurrence, Local - drug therapy; Neoplasm Recurrence, Local - pathology; Non-Randomized Controlled Trials as Topic; Prognosis; Survival Rate; Vorinostat - administration & dosage; World Health Organization
• ISSN: 1083-7159; 1549-490X; 1549-490X
• DOI: 10.1634/theoncologist.2017-0501

Lessons Learned Combination regimen with bevacizumab (BEV) and vorinostat is well tolerated in patients with recurrent glioblastoma. Treatment of recurrent glioblastoma remains challenging as this study and others attempt to improve progression‐free survival and overall survival with BEV‐containing...